More than half a million people with cancer will die this year; our mission is to be your one source to improve people's health and lives.
From hundreds of preclinical tumor models and cell line assays to oncology clinical trials and post-market studies, we can help you get your next breakthrough cancer drug or precision medicine treatment to those who desperately need it.
We're committed to helping you and your loved ones find personalized cancer care options. That's why we teamed up with WIRED Brand Lab to show how our simple blood test is making targeted cancer therapies more accessible. Produced by WIRED Brand Lab with Labcorp.
In the last five years, our expertise, insights and market impact have been demonstrated in excess of 975 oncology studies (300 in immuno-oncology) across nearly 19,000 sites in 83 countries with more than 104,000 oncology patients.
Embrace a personalized medicine approach that targets therapies to specific subsets of patients and begins in the preclinical phase of drug development.
Utilize biomarkers in clinical oncology development to provide key data for earlier decision making as well as patient and site selection
Codevelop a drug with oncology companion diagnostics to help identify patients most likely to benefit from your next cancer breakthrough
业界已经从许多角度研究了免疫肿瘤学，因此需要鉴定、研发和完善能够概括最佳生物动力学以及关联和相关终点的模型。
要在用于临床试验的精准医药方面取得进展，就必须采用新颖的方法进行快速测试并为合适的个体提供合适的疗法。 In addition to dozens of late-stage immuno-oncology clinical trials, we have also supported more than 70% of all FDA-approved companion diagnostic products.
让我们开始对话
联系我们.png){kind=icon}
